Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70809, United States
NCT Number: NCT04774081
This study will determine whether the ratio between 24h C-peptide urinary excretion rate and average 24h circulating glucose represent a good correlate of what is measured by the gold standard, i.e. M (glucose disposal rate) from a euglycemic-hyperinsulinemic clamp
Looking for future studies?
Notify Me18 year–65 year
All sexes
Observational
Baton Rouge, Louisiana, 70809, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be admitted to the research clinic for a 24-hour stay in a metabolic chamber. During the chamber stay, all urine excreted will be collected to assess C-peptide urinary excretion rate and interstitial glucose will be measured by a continuous glucose monitor (CGM). Participants will consume a eucaloric diet (50% carbohydrates, 30% fat and 20% protein).
Time frame: 24 hours
Time frame: 24 hours
Time frame: Up to 5 years before the CGM and C-peptide assessment
Pennington Biomedical Research Center
Other
Acronym: CGM-PEPTIDE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04264897
Aging, Chronic Disease
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT05764200
Glucose Metabolism Disorders, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Maastricht, Netherlands
View Trial DetailsNCT07194772
Glucose Homeostasis, Glucose Intolerance
Ottawa, Ontario, Canada
View Trial DetailsNCT03479671
Diabetes Mellitus, Diabetes Mellitus, Type 2
Philadelphia, Pennsylvania, United States
View Trial Details